Identify and Validate Innovative Peptides for the Treatment of Obesity
The Pharma Data
MARCH 2, 2021
This new collaboration builds on the positive experience from previous partnerships with Gubra and combines Gubra’s proprietary streaMLine platform and expertise in obesity and peptide chemistry with Boehringer Ingelheim’s expertise in lead optimization and clinical development. population will have obesity. About Boehringer Ingelheim.
Let's personalize your content